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A B S T R A C T
Background: Electronic health records are frequently used for cancer epidemiology. We report on their quality
for ascertaining colorectal cancer (CRC) in UK women.
Methods: Population-based, retrospective cohort study nested within the UK Collaborative Trial of Ovarian
Cancer Screening (UKCTOCS). Postmenopausal women aged 50–74 who were diagnosed with CRC during
2001–11 following randomisation to the UKCTOCS were identified and their diagnosis confirmed with their
treating clinician. The sensitivity and positive predictive value (PPV) of cancer and death registries, hospital
episode statistics, and self-reporting were calculated by pairwise comparisons to the treating clinician’s con-
firmation, while specificity and negative predictive value were estimated relative to expected cases.
Results: Notification of CRC events were received for 1,085 women as of 24 May 2011. Responses were received
from 61% (660/1,085) of clinicians contacted. Nineteen women were excluded (18 no diagnosis date, one di-
agnosed after cut-off). Of the 641 eligible, 514 had CRC, 24 had a benign polyp, and 103 had neither diagnosis.
The sensitivity of cancer registrations at one- and six-years post-diagnosis was 92 (95% CI 90–94) and 99%
(97–100), respectively, with a PPV of 95% (95% CI 92/93–97). The sensitivity & PPV of cancer registrations (at
one-year post-diagnosis) & hospital episode statistics combined were 98 (96–99) and 92% (89–94), respectively.
Conclusions: Cancer and death registrations in the UK are a reliable resource for CRC ascertainment in women.
Hospital episode statistics can supplement delays in cancer registration. Self-reporting seems less reliable.
1. Background
Electronic health records (EHRs) are datasets created for routine
administrative purposes. Increasingly, however, they are used to assess
health outcomes in large observational studies and randomised con-
trolled trials [1–5]. Evaluating their quality is therefore crucial.
National registries are responsible for cancer registration (CR) in
Northern Ireland, Scotland, and Wales, while cancers diagnosed in
England are registered by one of eight regional hubs. English registries
have been shown by one-directional comparisons to capture 98% of
colorectal cancers (CRCs) recorded in routine healthcare databases
[6,7]. However, such estimates are likely overestimated since it is un-
likely for an individual database to have complete coverage of all
events, while iterative refinements to the registration process require
ongoing evaluations.
Hospital episode statistics (HES) is an administrative dataset that
documents all admissions and attendances to NHS Trusts in England. Its
secondary uses for research has been reviewed [8]. HES is appealing
since the compulsory recording of hospital events, each year, amasses
∼125-million diagnostic and procedural records amenable to digital
analyses [9], while their coding from case notes by dedicated profes-
sionals is generally accurate [10,11]. Despite the extensive coverage of
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CRC events recorded in HES [12], its reliability has not been de-
termined.
Self-reporting (SR), meanwhile, remains an option for identifying
events where EHRs are unavailable or inaccessible. However, the re-
liability of self-reporting is currently unclear, particularly in spite of
increased detection of adenomatous polyps [13] and potential confu-
sion resulting from repeat testing due to technical issues and false po-
sitive screening tests [14].
We herein determined the feasibility of using EHRs and self-re-
porting for CRC ascertainment in UK women. We report on the sensi-
tivity and positive predictive value (PPV) of cancer and death regis-
trations, HES, and self-reporting relative to treating clinician’s
confirmation. We also explore the reliability of self-reporting of CRC
and the factors that determine the accurate self-reporting of CRC.
2. Methods
2.1. Study design
The present retrospective cohort study was nested within the UK
Collaborative Trial of Ovarian Screening (UKCTOCS). During 2001–05,
202,638 postmenopausal women aged 50–74 were randomised to
UKCTOCS trial centres across England, Northern Ireland, and Wales
following an invitation from health authorities [15]. All were asked to
provide their ethnicity, postcode, height, and weight by postal ques-
tionnaire at recruitment. Postcodes were updated throughout the trial.
The study cohort were women who were identified as having been di-
agnosed with CRC since randomisation (see Data sources) and gave
consent for access to their medical records (see Clinician’s confirmation).
2.2. Data sources
2.2.1. Electronic health records
Women were linked to their EHRs by NHS number. CRs were up-to-
date until 19 May 2011 for England & Wales and 23 February 2010 for
Northern Ireland. DCs were up-to-date until 19 May 2011 for England &
Wales and 9 March 2011 for Northern Ireland. In- and outpatient HES
were received for those in England from 2001 and 2003, respectively,
until 22 July 2010. CR, DC, and HES records were reviewed for ma-
lignant neoplasms of the colon or rectum (ICD10 C18–C20) diagnosed
following randomisation to the UKCTCOS. Duration of follow-up was
calculated from the date of randomisation to the date of the latest up-
date (or date of loss to follow-up if before).
2.2.2. Postal questionnaire
All participants were able to self-report CRC using postal ques-
tionnaires first sent at 3–5-years post-randomisation (FUQ I) and
thereafter in April 2014 (FUQ II) [15]. Each questionnaire included an
item on whether the woman had been diagnosed with ‘bowel/colorectal
cancer’. FUQ I also requested data on their education (college/uni-
versity degree or nursing/teaching qualification or A-/O-level or vo-
cational qualification or other or none of the above) alcohol use (how
many units consumed on average per week), and smoking habit (never/
ever).
2.2.3. Trial database
Incidental notifications were received via the UKCTOCS staff due to
1) investigation of a possible ovarian cancer diagnosis after a positive
screening result or 2) a participant citing colorectal cancer diagnosis as
a reason for withdrawal from the trial. Half of all UKCTOCS women
were screened via annual serum CA125 (25%) or transvaginal ultra-
sound (25%), while the remaining half were controls who received no
screening.
2.3. Clinician’s confirmation
All women with a possible CRC diagnosis was identified on 24 May
2011. In May 2012, a postal questionnaire (CRCQ) was sent to the
treating clinician (GP by default or treating hospital consultant if self-
reported in the FUQ I), requesting the diagnosis date, primary site,
stage, grade, morphology, and treatment details (Supplementary Fig.
S1). The CRCQ requested details of a specialist if the initial contact was
unable to provide complete data, who was contacted if necessary.
Reminder CRCQs were sent to non-responding clinicians. Questionnaire
outcomes (confirmed CRC, benign polyp, no CRC or benign polyp) were
captured in the UKCTOCS Trial Management System. Where multiple
CRCQs per women were obtained, a confirmed CRC superseded one
which reported a benign diagnosis. The earliest of two cancer diagnosis
dates was used where necessary. Cancers without a diagnosis date and
those diagnosed after 24 May 2011 were excluded.
2.4. Data analyses
2.4.1. Non-response bias
The likelihood of a non-response bias was accessed by multivariable
analysis (Kruskal-Wallis/Fisher’s Exact & post-hoc pairwise Wilcox rank
sum/χ2 with Bonferroni adjustment) of the characteristics and com-
position of notifications for women with a clinician's confiration and
those whose clinician did not respond.
2.4.2. Sensitivity & PPV
The number of true positive (TP), true negative (TN), false positive
(FP), and false negatives (FN) notifications for each dataset were de-
termined by pairwise comparison to clinician’s confirmation (gold-
standard). The sensitivity (TP/(TP+ FN)), PPV (TP/(TP+ FP)), and
95% confidence intervals were then computed for each data source. The
CR analysis included events diagnosed ≥ one year before the latest
registry update (19 May 2010 for England & Wales and 23 February
2009 for Northern Ireland). The DC analysis included only cancers with
death dates before the latest update (19 May 2011 for England & Wales
or 9 March 2011 for Northern Ireland). For HES, only women from
English centres with a diagnosis date before 22 July 2010 (HES update
22 July 2010) were included. Our SR analysis included women who had
a diagnosis date before the date their FUQ I or II was returned. The use
of EHRs and SR to complement delays in CRs was also assessed via
comparison of the adjunct sensitivities and PPVs for CRCs diagnosed
≥1 year in advance of latest registry update. Adjunct analyses of CR &
HES and CR & DC & HES were restricted to England.
2.4.3. Timeliness and completeness
We assessed the completeness of CRs by determining the proportion
(%) of all confirmed cancers that were registered in updates received by
4 September 2016 for England & Wales and 15 April 2015 for Northern
Ireland. Curation times for CRs were defined as the years between di-
agnosis and latest update.
2.4.4. Specificity & NPV
Specificities and negative predictive values (NPVs) were estimated
relative to the expected number of cases derived from an age-standar-
dised rate of 57.2 cases per 100,000 person-years [16] and total years of
follow-up. Full details are disclosed in Supplementary Method M1.
2.4.5. Determinants of accurate self-reporting
A binomial logistic regression model was fitted to identify the
variables predictive for self-reporting concordant with the clinician’s
confirmation. The analysis was restricted to those who returned their
FUQ. Outcomes were either concordant (TP & TN) or discordant (FP &
FN) self-reporting. Predictive determinants were age (at self-report),
BMI (at recruitment to the UKCTOCS), education (low: A-/O-level or
vocational qualification; high: college/university degree or nursing/
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teaching qualification; other: none of the above), alcohol use (non-
drinker/< 1 unit per day/≥1 unit per day), smoking habit (never/
ever), and socioeconomic status (Index of Multiple Deprivation 2015
(IMD) derived from postcode (England only)). The IMD is a composite
measure of seven socioeconomic indicators that stratifies all English
postcodes on a gradient from most to least deprived [17]. Outliers (> 3
SD of the mean/±1.5 IQR) were entered as missing. Missing data were
imputed five times using predictive mean matching. Logit coefficients
for each imputed dataset were pooled according to Rubin’s rules [18].
Odds ratios were adjusted for all variables listed.
2.4.6. Statistical analyses
Five-way Venn diagrams were produced using the online
InteractiVenn tool [19]. All other analyses were made with R version
3.3.2 [20] running the epiR, ggplot2, mice, and outliers packages. A p
value< 0.05 was considered significant.
Fig. 1. Study overview. All women enrolled in the UKCTOCS were monitored for CRCs diagnosed since being randomised via linkage to electronic health records,
self-reporting, and by information discerned via the trial itself. The treating clinician or general practitioner of each woman notified to us were contacted for
clinician’s confirmation of all events. Apparent performances of electronic health records and self-reporting were assessed against the outcome of clinician’s con-
firmation. Completeness of cancer registrations at 19 May 2010 (England & Wales)/ 23 February 2009 (Northern Ireland) was compared to those received by 04
September 2016 (England & Wales)/ 15 April 2015 (Northern Ireland). 1 England only. Abbreviations: UKCTOCS, UK Collaborative Trial of Ovarian Cancer
Screening; CR, cancer registration; DC, death certification; HES, Hospital Episode Statistics; SR, self-reporting; CRCQ, colorectal cancer questionnaire; HC, clinician’s
confirmation; GP, general practitioner; IMD, Index of Multiple Deprivation; EHR, electronic health records (CR, DC, HES).
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3. Results
We received 2,217 notifications of a post-randomisation CRC diag-
nosis for 1,085 women (Fig. 1). These included 814 CRs, 233 DCs, 625
HES, 400 SRs (FUQ I only), and 145 notifications via the trial database.
Clinicians of all 1,085 women were sent a CRCQ. Responses were re-
ceived from 660 (61%). Nineteen women were excluded as 18 of the
confirmed cancers had no diagnosis date on the returned CRCQ and one
cancer was diagnosed after May 2011 (self-reported in 2006). Overall,
641 women were eligible for analysis. Of these, 514 had a verified CRC,
24 had a benign polyp, while 103 had never been diagnosed with
malignant or benign colorectal disease. Histology reports were dis-
closed for 15% (75/514) of verified CRCs. There were 1,173 TP noti-
fications and 152 FP notifications (38 for benign disease, 114 for no
malignant/benign diagnosis).
The contribution of each notification to the pools of TPs and FPs is
presented in Supplementary Fig. S2. Cancer registrations contributed to
38.6% (453) of 1,173 TP notifications, followed by HES (27.9% (327)),
self-reporting (18.0% (211)), death certificates (8.4% (98)), and trial
resources (7.2% (84)). CRs provided the greatest contribution of un-
iquely recorded TPs (4.6% (54)), while SR (0.7% (8)) and DC (0.3% (4))
provided few. Overlap in TP events between two datasets ranked in
order of CR & HES (38.2% (298/780)), CR & SR (29.1% (193/664)),
HES & SR (23.8% (128/538)), DC & HES (16.2% (69/425)), CR & DC
(15.8% (87/551)), and DC & SR (2.6% (8/309)) (Supplementary Fig.
S2a). Contributions to the pool of 152 FP notifications ranked in order
of SR (62.5% (95)), CR (16.4% (25)), HES (14.5% (22)), trial resources
(5.3% (8)), and DC (1.3% (2)) (Supplementary Fig. S2b). Notably,
58.6% (89) of FPs were uniquely notified by SR—eight where a benign
adenoma was present and 84 where no benign/malignant diagnoses
were verified.
Baseline characteristics are presented in Table 1 (& further stratified
in Supplementary Table S1). Women whose clinicians did not respond
(NR) had a greater proportion of notifications informed by DC (15%) to
TPs (8%) and FPs (1%). NRs and TPs were similar but differed to FPs in
their proportion of notifications informed by CR (37, 39%, & 16%, re-
spectively), HES notifications (26, 28, and 14%), and SR (16, 18, &
62%). NRs were comparable to TPs in their age, BMI, ethnicity, edu-
cation, alcohol use, and smoking habit and differed to FPs in age, IMD
score, education, alcohol use, and smoking habit (Table 1). NRs had a
markedly greater proportion of deaths (38%) than FPs (5%) and TPs
(24%).
3.1. Cancer registrations
The sensitivity and PPV were estimated from 618 verified women
(491 with CRC diagnosed one year before the latest update, 24 with a
benign polyp, 103 with no colorectal disease). Median follow-up from
randomisation to registry update or loss to follow-up was 6.5 years (IQR
2.1; n 618). Curation times ranged from 1.0 to 9.1 years (median 4.1;
IQR 3.2; n 491).
CR notified of 54 unique TP events not captured by other sources.
There were 38 CRCs without a CR after a minimum of one-year cura-
tion. Of these, 32 were registered when curation was extended to
6.3–14.4 years (median 9.4; IQR 3.2), while six residents in England
remained unregistered after 6.8, 7.5, 10.5, 11.5, 13.1, and 13.6 years of
curation (Table 2b & Supplementary Table S2). Four of the FP regis-
trations (2 benign and 2 no CRC) were rescinded by 2015/16, while 2
TN (1 benign and 1 no CRC) became FP. Overall, a further 36 women
were correctly classified (32 CRC TPs and 2 benign & 2 no CRC TNs)
and two were incorrectly registered (1 benign & 1 no CRC FPs) when
curation was extended.
The sensitivity and PPV of CR after allowing a minimum of 1 year for
their curation were 92% (453/491; 95% CI 90–94) and 95% (453/478;
95% CI 92–97), respectively (Table 3). When supplemented with regis-
trations received until 2015/16, the sensitivity of CR increased to 99%
(485/491; 95% CI 97–100), while the PPV remained at 95% (485/508;
95% CI 93–97). Sensitivities by year of diagnosis (2002–2010 in-
clusively) after a minimum of one or six years of curation are presented
in Fig. 2. Specificity and NPV were estimated from 202,230 women.
Relative to the 850 cases expected after 1,486,350 person-years follow-
up, the specificity and NPV were 100% (201,485/201,515; 95% CI
100–100) and 100% (201,485/201,551; 95% CI 100–100), respectively.
Table 1
Non-responders show notable similarities to True Positives and differences to
False Positives.
Cohort p valuea
Responders
(TP)
Responders
(FP)
Non-
responders
(NR)
Median (Range)
Age 72 (57–83) 68 (57–82) 72 (57–83) NR vs. FP
(0.018)
BMI (Kg m-2) 25.8
(10.3–110.8)
26.4
(18.7–150.0)
25.6
(0.1–47.2)
0.753
IMD score 13.6
(1.6–73.9)
11.4
(2.5–74.4)
16.4
(1.6–70.8)
NR vs. TP
(0.011)
& FP
(0.003)
Count (%)
Cohort size 514 (100) 127 (100) 425 (100)
Alcohol NR vs. FP
(< 0.001)
Non-drinker 83 (16) 16 (13) 71 (17)
< 1 unit a
day
178 (35) 67 (53) 124 (29)
≥ 1 unit a
day
71 (14) 37 (29) 55 (13)
Missing 182 (35) 7 (6) 175 (41)
Deathsb NR Vs. TP
(< 0.001)
& FP (<
0.001)
Alive 390 (76) 121 (95) 263 (62)
Deceased 124 (24) 6 (5) 162 (38)
Education NR vs. FP
(< 0.001)
Low 131 (25) 50 (39) 104 (24)
High 89 (17) 43 (34) 54 (13)
Other 106 (21) 25 (20) 95 (22)
Missing 188 (37) 9 (7) 172 (40)
Ethnicity 0.821
White 493 (96) 124 (98) 411 (97)
Black 9 (2) 2 (2) 7 (2)
Other 9 (2) 1 (1) 3 (1)
Missing 3 (1) 0 (0) 4 (1)
Smoking NR vs. FP
(< 0.001)
Ever 109 (21) 43 (34) 120 (28)
Never 187 (36) 64 (50) 135 (32)
Missing 218 (42) 20 (16) 170 (40)
Notifications 1,173 (100) 152 (100) 841 (100) NR vs. TP
(0.001)
& FP (<
0.001)
CR 453 (39) 25 (16) 312 (37)
DC 98 (8) 2 (1) 125 (15)
HES 327 (28) 22 (14) 220 (26)
SR 211 (18) 95 (62) 137 (16)
Trial 84 (7) 8 (5) 47 (6)
a p values refer to the multivariable test (Kruskal-Wallis/Fisher’s Exact) if no
significance detected or the Bonferroni-adjusted, pairwise post-hoc test(s)
(pairwise Wilcox rank sum/χ2) if significance detected.
b at clinician’s confirmation. Abbreviations: TP; True Positives (Responders);
FP, False Positives (Responders); NR, Non-responders; CRCQ, Colorectal Cancer
Questionnaire.
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3.2. Death registrations
Sensitivity and PPV were estimated from the 104/641 (16.2%)
verified women who died before the latest DC update (102 cancers
diagnosed before the latest update, 2 with no cancer/benign
(Table 2c)). Median follow-up from randomisation to registry update or
loss to follow-up was 4.8 years (IQR 3.2; n 104). The sensitivity and
PPV of DCs were 97% (98/102; 95% CI 92–99) and 98% (98/101; 95%
CI 93–100), respectively (Table 3). Specificity and NPV were estimated
from 7,202 registered deaths. Relative to the 19 cases expected after
33,968 person-years follow-up, the specificity and NPV were 97%
(6,968/7,183; 95% CI 97–97) and 100% (6,968/6,969; 95% CI
100–100), respectively.
3.3. Hospital episode statistics
The sensitivity and PPV were estimated from 502 verified women
who were randomised from centres in England (397 with confirmed
CRC diagnosed before 22 July 2010, 21 with a benign polyp, 84 with no
colorectal disease (Table 2d)). Median follow-up from randomisation to
Table 2
Distribution of true and false notifications by data source.
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HES update or loss to follow-up was 6.7 years (IQR 2.2; n 502). Eleven
TP HES notifications were unique and were all diagnosed in 2008–09.
The sensitivity and PPV for HES notifications were 82% (327/397; 95%
CI 78–86) and 94% (327/349; 95% CI 91–96), respectively (Table 3).
Specificity and NPV were estimated from 157,839 women in England.
Relative to the 616 cases expected after 1,076,512 person-years follow-
up, the specificity and NPV were 100% (157,105/157,223; 95% CI
100–100) and 100% (157,105/157,214; 95% CI 100–100), respec-
tively.
3.4. Self-reporting
Of 641 eligible women, 353 (55.1%) completed a FUQ (291 FUQ1,
62 FUQ II). Of these, 233 had a confirmed CRC, 22 had a benign polyp,
and 98 had no malignant/benign colorectal disease (Table 2e–f). The
sensitivity and PPV of SR in the cohort of responders were 91% (211/
233; 95% CI 86–94) and 69% (211/306; 95% CI 63–74), respectively
(Table 3). The sensitivity where non-responses were negative by default
was 41% (211/514; 95% CI 37–45) at a 69% PPV. Specificity and NPV
were estimated from 144,313 women who returned their FUQ. Relative
to the 321 cases expected after 561,274 person-years follow-up, the
specificity and NPV were 100% (143,883/143,992; 95% CI 100–100)
and 100% (143,883/143,913; 95% CI 100–100), respectively.
We fitted a logistic regression to ascertain the variables associated
with concordant self-reporting. The adjusted ORs are presented in
Table 4. Missing data were imputed for IMD (83 (9 England, 22
Northern Ireland, 52 Wales)), smoking (51), education (13), alcohol
(8), age at self-report (4), and BMI (3 including 1 outlier). Baseline
characteristics for women included in this model are summarised in
Supplementary Table S1. Age at self-report markedly increased the odds
of being concordant with their clinician’s confirmation (adjusted OR
1.05; 95% CI 1.01–1.10; p 0.026). No other associations were statisti-
cally significant.
3.5. Trial database
Notification via the UKCTOCS trial centre accounted for few of the
overall TP (7.2%; 84/1,173), FP benign (7.9%; 3/38), and FP no CRC/
benign notifications (4.4%; 5/114) but captured 12 events that would
have otherwise been missed (Supplementary Fig. S2a). The majority of
Table 3
Performance estimates for electronic health records and self-reporting.
Dataset Sensitivitya
(95% CIs)
PPVa
(95% CIs)
Specificityb
(95% CIs)
NPVb
(95% CIs)
CRc 0.92 (0.90–0.94) 0.95 (0.92–0.97) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
CRd 0.99 (0.97–1.00) 0.95 (0.93–0.97) — —
DC 0.97 (0.92–0.99) 0.98 (0.93–1.00) 0.97 (0.97–0.97) 1.00 (1.00–1.00)
HES 0.82 (0.78–0.86) 0.94 (0.91–0.96) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
SRd 0.91 (0.86–0.94) 0.69 (0.63–0.74) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
a relative to clinician’s confirmation.
b relative to expected cases.
c 1–9 years curation (median 4.1, IQR 3.2).
d 6–14 years curation (median 9.4, IQR 3.2). Abbreviations: PPV, positive predictive value; NPV, negative predictive value; CIs, confidence intervals; CR, cancer
registration; DC, death certificate; HES, Hospital Episode Statistics; SR, self-reporting.
Fig. 2. Sensitivity of cancer registrations curated after a
minimum of 1 & 6.3 years. Sensitivities by year of diagnosis
(2002–10 inclusively) were 100, 92, 100, 99, 99, 99, 73, 88,
and 91% with allowance of 1.0–9.1 years curation (CR update
in 2010/11) and 100, 92, 100, 99, 99, 100, 100, 98, and 100%
when supplemented with registrations received until 2015/16
(6.3–14.4 years curation).
Table 4
Variables associated with self-reporting concordant with clinician’s confirma-
tion.
Variable ORa (95% CIs) p value
(Intercept) 0.22 (0.01–7.53) 0.395
Age (year) 1.05 (1.01–1.10) 0.026*
BMI (Kg/m2) 0.98 (0.91–1.05) 0.504
IMD score 1.01 (0.98–1.04) 0.441
Alcohol
0 1.00
< 1 U/day 0.48 (0.20–1.13) 0.091
> 1 U/day 0.38 (0.15–1.00) 0.051
Smoking
Never 1.00
Ever 1.18 (0.63–2.19) 0.604
Education
Low 1.00
High 1.19 (0.60–2.36) 0.613
Other 0.86 (0.41–1.83) 0.698
a Adjusted for all variables listed. n 353. Age at self-report. Abbreviations:
OR, odds ratio; BMI, Body Mass Index; IMD, Index of Multiple Deprivation.
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TPs (84.5% (71/84)) and FPs (87.5% (7/8)) were informed by reasons
for withdrawal from the UKCTOCS.
3.6. Adjunct datasets
Given the demonstrated delay in cancer registrations, researchers
may be interested in how best to supplement their analyses. There were
38 cancers not registered 1 year after diagnosis (36 in England). HES,
SR, and DC captured 77.8% (28/36), 36.8% (14/38), and 21.1% (8/38)
of these events, respectively. The sensitivity and PPV of CR & HES (n
501) were 98% (388/396; 95% CI 96–99) and 92% (388/422; 95% CI
89–94); CR & SR (n 618): 95% (467/491; 95% CI 93–97) and 80%
(467/581; 95% CI 77–84); and CR & DC (n 618): 94% (461/491; 95%
CI 91–96) and 95% (461/487; 95% CI 92–96). The sensitivity and PPV
of CR, DC & HES combined (n 501) were 98% (388/396; 95% CI 96–99)
and 92% (388/422; 95% CI 89–94).
4. Discussion
Advances in healthcare are achieved through high-quality epide-
miological studies informed by a comprehensive and reliable ascer-
tainment of outcomes. We have herein evaluated the performance of
EHRs in addition to self-reporting for ascertaining diagnoses of CRC in
UK women in comparison to a patient’s clinical records. We found that
92% of CRCs diagnosed in the UK during 2001–10 were registered
within one year, and 99% within six years. Researchers looking to
overcome delays in the curation of cancer registrations are advised to
use HES in adjunct, which combined had a sensitivity of 98% and a PPV
of 92%. Finally, self-reporting of CRC for standalone or adjunct ascer-
tainment was not useful owing to high false positivity and low response
rates.
Registration of cancers by regional registries are the cornerstone of
national and international cancer surveillance [21] and have hitherto
informed the implementation of CRC screening programmes [1,2]. An
incomplete ascertainment of events, however, can skew analyses.
Nonetheless, our group previously concluded that incomplete registra-
tion of CRC is unlikely as 85% of self-reported (but not verified) CRCs
were registered within five years of diagnosis [22]. The higher sensi-
tivity of CRC cancer registration reported here (92% vs 85%) is likely
due to our exclusion of previously unknown false positive self-reported
CRCs. Elsewhere, it is reported that 98% of surgically treated CRCs
recorded in HES during 2001–07 were registered [6], while 98% of
primary care records were captured within four years [7].
We found no issues with the reliability of HES (PPV 94%). This is in
alignment with a recent meta-analysis [10]. HES did, however, have
limited sensitivity that would likely preclude its use for standalone
ascertainment. These missed cases are likely due to coding errors,
emergency admissions, death certificate-only registrations, or privately-
treated patients. Nonetheless, a similar sensitivity (83%) was reported
for prostate cancers recorded by HES relative to medical notes [23].
Self-reporting of CRC by post was unreliable. While the sensitivity
(91%) of responders was similar to CR at one year (92%), a low re-
sponse rate (55%) limited the sensitivity to 41%. Furthermore, the PPV
was 69%, and some women misreported their benign polyp as cancer.
Studies in the USA have reported similar sensitivities (83–85%) for
postal self-report, albeit at a lower PPV (54%) [24,25]. Our findings
align with reports that British interviewees markedly under-report CRC
diagnoses in close relatives [26], but contrasts in that they reliably self-
report their participation in CRC screening [27]. As screening becomes
widely accepted, an ongoing evaluation of how it might influence the
layperson’s ability to reliably self-report would be insightful.
Our study has several limitations. Firstly, we did not verify the
absence of cancer in those without a notification, and thus the relia-
bility of the sensitivity estimates are dependent on the number of false
negatives missed. Secondly, the potential for bias in the 39% of non-
responding clinicians contacted should not be overlooked for an
underascertainment of FPs through non-response would overstate the
PPV, while an underascertainment of TPs would underestimate the
sensitivity. Nonetheless, barring a higher proportion of mortality at
point of clinician contact and notifications via death certificate, non-
responders were in closer alignment to TPs than FPs in the notifications
received, and we suspect the risk of bias to be minimal. Next are issues
of generalisability. Men are disproportionally affected by CRC [16]
while also being less likely to undertake FOBT screening than women
[28], but were not studied here. Ethnic minorities, too, are less likely to
undertake screening [28] but were underrepresented in our cohort.
Finally, our findings may be affected by ‘healthy-volunteer’ bias that
typically affects those willing to enrol in trials [29], while it would also
be reasonable to assume that recall biases arising from past diagnoses of
CRC in the family or prior colonoscopy for suspected cancer could aid
concordant self-reporting and would, ideally, be accounted for in ana-
lyses if obtained.
Weaknesses notwithstanding, our study updates the current per-
formance estimates of colorectal cancer registrations [6,7]. Our esti-
mates are reliable though us studying verified events identified via
myriad routes. It is strengthened further from the high rate at which
patients’ EHRs were linked.
5. Conclusions
Electronic health records in England, Northern Ireland & Wales are
a reliable resource for ascertaining colorectal cancer events in women.
Researchers looking to supplement delays in the registration of CRCs
should use hospital episode statistics in adjunct. Self-reporting of col-
orectal cancer by women is neither reliable nor is it useful in adjunct
with electronic health records.
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